Hemostatic Gel

Hemostatic Gel Market Outlook

The global hemostatic gel market is anticipated to reach approximately USD 2.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 5.6% from 2025 to 2035. This growth is driven by an increasing surgical volume, rising incidences of trauma cases, and a growing demand for minimally invasive surgical procedures. Moreover, advancements in medical technology, such as the development of innovative hemostatic agents that offer faster clotting times and improved biocompatibility, are also propelling market expansion. The increasing prevalence of chronic diseases, which frequently require surgical interventions, adds to the demand for hemostatic products. Additionally, the rising geriatric population, who are more susceptible to injuries and surgical requirements, is expected to significantly contribute to the market growth.

Growth Factor of the Market

Several factors are contributing to the robust growth of the hemostatic gel market. Firstly, the rising incidence of road accidents and trauma cases has led to a heightened demand for effective hemostatic solutions that can control bleeding during emergencies. Secondly, the global rise in the number of surgeries, including orthopedic, cardiovascular, and neurosurgical procedures, has significantly increased the need for reliable hemostatic agents to ensure patient safety during operations. Thirdly, hospitals and surgical centers are increasingly adopting advanced technologies, which include hemostatic gels, that promise improved patient outcomes and faster recovery times. Furthermore, increasing healthcare expenditure, especially in emerging markets, is anticipated to fuel the adoption of advanced medical products, including hemostatic gels. Lastly, ongoing research and development aimed at enhancing the efficacy and safety of hemostatic products are expected to open new avenues for market growth.

Key Highlights of the Market

• The hemostatic gel market is projected to grow significantly, reaching USD 2.5 billion by 2035.
• Thrombin-based hemostatic gels are expected to dominate market revenue due to their effectiveness and wide usage in surgeries.
• The surgical hemostasis application segment is anticipated to hold the largest market share, driven by increasing surgical procedures globally.
• North America is expected to lead the market, attributed to advanced healthcare infrastructure and high surgical volumes.
• R&D initiatives for the development of novel hemostatic gels are expected to foster market innovation and expansion.

By Product Type

Thrombin-Based Hemostatic Gel:

Thrombin-based hemostatic gels are one of the most widely used products in surgical settings, known for their rapid clotting capabilities. These gels work by leveraging thrombin, a crucial enzyme in the coagulation cascade, to enhance the body's natural hemostatic process. They are particularly favored in surgeries where rapid hemostatic action is critical, such as orthopedic and cardiovascular procedures. The market for thrombin-based gels is bolstered by ongoing clinical studies and positive feedback from healthcare professionals regarding their effectiveness in controlling bleeding. Furthermore, advancements in formulation techniques are improving the stability and application of these gels, thereby expanding their use in various surgical applications.

Collagen-Based Hemostatic Gel:

Collagen-based hemostatic gels are increasingly gaining traction due to their bioactive properties that promote wound healing and tissue regeneration. These gels enhance hemostasis by providing a scaffold for the accumulation of platelets and other cells involved in the clotting process. They are often utilized in dental, cosmetic, and orthopedic surgeries, where the need for tissue integration is paramount. The biocompatibility of collagen gels makes them suitable for a wide range of patients, including those with sensitivities to other hemostatic agents. As a result, increasing awareness about the benefits of collagen-based products is fostering their adoption in clinical settings.

Gelatin-Based Hemostatic Gel:

Gelatin-based hemostatic gels are valued for their versatility and rapid hemostatic properties. These gels work primarily by providing a physical barrier to bleeding and promoting platelet aggregation. They are particularly effective in controlling bleeding in minor surgeries and are increasingly being integrated into emergency first-aid kits due to their ease of use. The gelatin's biodegradable nature also appeals to healthcare providers looking for solutions that do not complicate post-operative recovery. The growing trend towards minimally invasive procedures is fostering an increase in the demand for gelatin-based hemostatic gels, as they are easy to administer and effective in various clinical scenarios.

Fibrin-Based Hemostatic Gel:

Fibrin-based hemostatic gels have gained popularity due to their unique composition that mimics the body's natural clotting process. They are particularly effective in surgeries where traditional hemostatic agents may not be sufficient. Fibrin gels facilitate the formation of a stable clot, while also encouraging tissue healing and repair. Their application spans various medical fields, including cardiovascular and reconstructive surgeries, where there is a high need for effective hemostatic solutions. The increasing research into fibrin gel formulations is promising, leading to enhanced performance and broader acceptance in surgical practices.

Polysaccharide-Based Hemostatic Gel:

Polysaccharide-based hemostatic gels are emerging as a compelling alternative in the market due to their high absorbency and ability to promote rapid hemostasis. These gels facilitate the formation of a natural clot by interacting with blood components such as platelets and red blood cells. Moreover, their biocompatibility and non-toxic properties make them suitable for use in sensitive surgical environments. As innovations continue to enhance the efficacy of polysaccharide gels, their application in various surgical procedures is expected to grow, further diversifying the hemostatic gel market.

By Application

Surgical Hemostasis:

The surgical hemostasis application segment is anticipated to maintain a significant market share due to the increasing number of surgical procedures performed globally, including elective and emergency surgeries. Hemostatic gels play a critical role in managing bleeding during operations, thereby enhancing patient safety and improving overall surgical outcomes. The growing trend of minimally invasive surgeries is expected to further drive the demand for effective hemostatic agents. As surgical techniques evolve, there is a continuous need for innovative hemostatic products that provide rapid and effective hemostasis without compromising tissue integrity, which is fueling the growth of this segment.

Trauma Hemostasis:

Trauma hemostasis is another crucial application area for hemostatic gels, as they are critical in emergency situations where rapid bleeding control is necessary. With the increasing incidence of road traffic accidents and other traumatic injuries, the demand for effective hemostatic agents in pre-hospital care is on the rise. Hemostatic gels are often used by first responders and in emergency medical services, providing a quick and effective solution for controlling external bleeding. This sector's growth is further enhanced by ongoing training programs aimed at equipping emergency medical personnel with the knowledge of using advanced hemostatic products.

Interventional Hemostasis:

Interventional hemostasis, which involves procedures such as catheterizations and minimally invasive surgeries, is becoming increasingly reliant on hemostatic gels for managing bleeding complications. The demand in this sector is driven by the rising prevalence of cardiovascular diseases and the growing number of interventional procedures performed annually. Hemostatic gels offer significant advantages in this setting, including ease of application and rapid action in controlling bleeding. As interventional techniques continue to evolve, the integration of innovative hemostatic solutions will be paramount, thereby fostering market growth.

Wound Hemostasis:

Wound hemostasis is a significant application for hemostatic gels, particularly in the management of chronic and surgical wounds. The aging population, which is more susceptible to wounds and skin injuries, is contributing to the increasing demand for hemostatic solutions in wound care. Hemostatic gels help to control bleeding and promote faster healing, making them essential in treating various wound types. The growing awareness of advanced wound care products among healthcare professionals is also expected to stimulate market growth in this segment.

Others:

Other applications of hemostatic gels include uses in cosmetic surgeries and veterinary medicine, where controlling bleeding is critical. The cosmetic surgery industry is witnessing significant growth, and the use of hemostatic gels to manage bleeding during procedures such as liposuction and facelifts is becoming more prevalent. Additionally, the veterinary sector is increasingly adopting hemostatic gels for surgical procedures and trauma care in animals. The expansion of these diverse applications is expected to broaden the market scope for hemostatic gels, creating new growth opportunities.

By Distribution Channel

Hospitals:

Hospitals hold a dominant share in the hemostatic gel market as they are the primary setting for surgical procedures and trauma care. In hospitals, hemostatic gels are utilized extensively in various surgeries, including orthopedic, cardiac, and general surgeries, where controlling bleeding is critical for patient safety. The growing number of surgical procedures performed in hospitals, coupled with the increasing investments in hospital infrastructure, is expected to drive the demand for hemostatic gels in this distribution channel. As hospitals continue to enhance their surgical capabilities, the reliance on effective hemostatic agents will further cement their market position.

Clinics:

Clinics are becoming increasingly important in the hemostatic gel market, particularly with the rise of outpatient surgical procedures. Many clinics are equipped to perform minor surgeries and procedures where effective hemostatic control is required. The growing trend toward outpatient care is expected to boost the demand for hemostatic gels in clinical settings, as these products enhance patient safety and optimize recovery times. This segment is supported by the increasing number of specialized clinics, such as dermatology and dental clinics, where hemostatic gels are commonly used.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are witnessing a surge in demand for hemostatic gels, primarily due to the increasing number of same-day discharge surgical procedures. ASCs offer a convenient and cost-effective alternative to traditional hospital surgeries, emphasizing the need for effective hemostatic solutions to ensure patient safety during these procedures. The rising focus on patient outcomes and the efficiency of surgical practices in ASCs is driving the adoption of hemostatic gels, making them a critical component in the surgical toolkit of these facilities.

Online Stores:

The rise of e-commerce has transformed the distribution landscape for medical products, including hemostatic gels. Online stores provide healthcare professionals and patients with easy access to a range of hemostatic products, often at competitive prices. The convenience of online shopping and the ability to compare various products have made it an increasingly popular choice for procuring medical supplies. This segment is expected to grow, as more suppliers and manufacturers enhance their online presence, catering to the demand for hemostatic gels in both professional and consumer markets.

Others:

Other distribution channels for hemostatic gels include pharmacies and medical supply stores, which play a supportive role in the overall market. While these channels may not dominate the market, they provide an essential service by making hemostatic products readily available to healthcare professionals and patients. The increasing prevalence of minor surgical procedures in non-hospital settings, coupled with the rising consumer awareness regarding advanced wound and bleeding management solutions, is expected to support the growth of hemostatic gels in these alternative distribution channels.

By Ingredient Type

Gelatin:

Gelatin is one of the primary ingredients used in the formulation of hemostatic gels, known for its effectiveness in promoting clot formation. The versatility of gelatin allows it to be processed into various forms, making it suitable for different applications, including surgical and wound management. Its biocompatibility and biodegradability further enhance its appeal, as it can be safely absorbed by the body after fulfilling its hemostatic function. The growing demand for gelatin-based products in the healthcare sector is anticipated to drive the growth of this ingredient type in the hemostatic gel market.

Thrombin:

Thrombin is a key ingredient in many hemostatic gels, responsible for accelerating the clotting process during surgery. It plays a vital role in the coagulation cascade, and its inclusion in hemostatic gels significantly enhances their effectiveness in controlling bleeding. As surgical procedures become more complex, the reliance on thrombin-based gels is expected to rise, promoting their use in various surgical settings. The increasing focus on patient safety and improved surgical outcomes will further bolster the demand for thrombin-based hemostatic gels in the market.

Collagen:

Collagen serves as an essential ingredient in hemostatic gels due to its natural bioactivity, promoting wound healing and tissue regeneration. By providing a scaffold for platelet aggregation, collagen-based gels facilitate clot formation and enhance the healing process. The rising awareness of the benefits of collagen in surgical and wound management is driving the growth of this ingredient type. As healthcare professionals increasingly seek products that not only control bleeding but also support tissue repair, collagen-based hemostatic gels are becoming a preferred choice in various medical applications.

Fibrin:

Fibrin is another critical ingredient in hemostatic gels, closely mimicking the body's natural clotting mechanism. Fibrin-based gels are particularly effective in surgical applications where rapid hemostasis is critical. The growth of minimally invasive surgical techniques has heightened the demand for fibrin-based products, as they provide effective bleeding control while minimizing trauma to surrounding tissues. As the healthcare industry continues to innovate, fibrin’s role in hemostatic gels is expected to expand, driving its market growth.

Polysaccharide:

Polysaccharides are emerging as a significant ingredient in hemostatic gels, recognized for their high absorbency and ability to promote rapid clot formation. These natural biopolymers enhance the hemostatic properties of gels by interacting with blood components, vital for effective bleeding control. The growing trend towards biocompatible products in the healthcare sector is likely to propel the demand for polysaccharide-based hemostatic gels. As manufacturers continue to innovate with polysaccharide formulations, their application across various medical fields is expected to increase.

By Region

North America holds the largest share of the hemostatic gel market, driven by the presence of advanced healthcare infrastructure, high surgical volumes, and increasing spending on healthcare solutions. The region's market is estimated to be valued at USD 1 billion in 2025 and is projected to grow at a CAGR of approximately 5.8% through 2035. The rise in chronic diseases and the aging population in North America are further propelling the demand for surgical procedures and hemostatic products. The regulatory environment in this region also fosters innovation and adoption of advanced hemostatic solutions, making it a key market for growth.

Europe is another significant region in the hemostatic gel market, accounting for approximately 30% of the global market share. The growth in Europe is primarily driven by the increasing number of surgical procedures, rising incidence of trauma cases, and a growing focus on advanced wound care solutions. The European market for hemostatic gels is expected to reach USD 700 million by 2035, with a CAGR of 5.3% during the forecast period. The region's growing emphasis on patient safety and effective hemostatic management is expected to further stimulate investment in hemostatic gel products, enhancing their market presence.

Opportunities

The hemostatic gel market is poised for numerous opportunities, driven by technological advancements and increasing healthcare needs. One significant opportunity lies in the development of next-generation hemostatic products that offer improved efficacy, safety, and ease of use. Research and innovation aimed at formulating hemostatic gels with enhanced biocompatibility and faster clotting times are expected to open new avenues for market growth. Additionally, the expansion of minimally invasive surgical techniques presents a substantial opportunity for hemostatic gels, as healthcare providers increasingly seek products that can provide effective hemostasis while minimizing trauma to tissues. This trend is further supported by ongoing training and education initiatives aimed at healthcare professionals regarding the benefits and techniques for using hemostatic gels, ultimately leading to increased market penetration.

Moreover, the rise of telemedicine and online consultations has also created a unique opportunity for the hemostatic gel market. As patients become more aware of advanced wound care solutions, the demand for these products through online platforms is expected to rise. This shift toward e-commerce and easy accessibility of hemostatic products can help suppliers and manufacturers reach a wider customer base, including individual consumers and healthcare providers in remote areas. Additionally, increasing investments in the healthcare sector, particularly in developing regions, present a promising opportunity for hemostatic gel manufacturers to expand their market presence and cater to the growing demand for medical products.

Threats

Despite the positive outlook for the hemostatic gel market, several threats could potentially impact its growth. One of the primary threats is the stringent regulatory landscape governing medical products, which can pose challenges to product approval and market entry. Manufacturers must navigate complex regulations and ensure compliance with safety and efficacy requirements, which can lead to delays in product launches and increased operational costs. Additionally, the presence of well-established competitors in the market may pose a barrier for new entrants and smaller companies seeking to innovate in the hemostatic gel sector. The competitive landscape's intensity can create pricing pressures that may reduce profit margins for companies operating in this space.

Furthermore, the emergence of alternative hemostatic agents and techniques may pose challenges to the hemostatic gel market. As new technologies and products develop, healthcare professionals may shift their preference towards these alternatives, potentially limiting the growth opportunities for hemostatic gel manufacturers. The ongoing evolution in healthcare practices, driven by advancements in medical technology, may also lead to changes in the demand for hemostatic solutions. Manufacturers must remain vigilant and adapt to these market dynamics to maintain their competitive edge and ensure sustained growth.

Competitor Outlook

• Johnson & Johnson
• Medtronic
• Smith & Nephew
• Ethicon, Inc.
• Hemostasis, LLC
• CSL Behring
• Advanced Medical Solutions Group plc
• BD (Becton, Dickinson and Company)
• Z-Medica, LLC
• Cohera Medical, Inc.
• Integra LifeSciences Corporation
• HemaQuell
• Biolife Plasma Services
• Vascular Solutions, Inc.
• Terumo Corporation

The competitive landscape of the hemostatic gel market is characterized by a mix of established players and emerging companies, all vying for market share in a growing industry. Major companies such as Johnson & Johnson and Medtronic have solidified their positions through their extensive product portfolios, robust distribution networks, and ongoing investments in research and development. These companies focus on innovation and are continuously working on new product formulations that enhance the efficiency and safety of their hemostatic gels. For instance, Johnson & Johnson has been at the forefront of developing advanced hemostatic solutions that cater to a wide range of surgical applications, reinforcing their leadership in the market. Additionally, these established companies often engage in strategic collaborations and partnerships to expand their product offerings and improve their market reach.

Emerging companies, such as Cohera Medical and Z-Medica, are making significant strides in the hemostatic gel market by introducing innovative products that meet the evolving needs of healthcare professionals. These companies often focus on niche markets and specific applications, allowing them to differentiate themselves from larger competitors. For instance, Cohera Medical's products are designed to provide effective hemostasis while promoting tissue healing and regeneration, appealing to healthcare providers looking for dual-function solutions. These emerging players are also leveraging technology and digital marketing strategies to enhance their visibility and outreach, further intensifying competition in the market.

As the hemostatic gel market continues to grow, competition among key players will likely intensify, leading to increased focus on product innovation and differentiation. Companies will need to prioritize customer needs and preferences while also ensuring compliance with regulatory standards. Additionally, as market dynamics evolve, companies must remain agile and adaptable to changing trends and technologies to maintain their competitive edge. Overall, the hemostatic gel market presents ample opportunities for both established and emerging players, with significant potential for growth and innovation in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 HemaQuell
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Behring
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Ethicon, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Z-Medica, LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Smith & Nephew
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hemostasis, LLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Terumo Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cohera Medical, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Biolife Plasma Services
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Vascular Solutions, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Integra LifeSciences Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Advanced Medical Solutions Group plc
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hemostatic Gel Market, By Application
    • 6.1.1 Surgical Hemostasis
    • 6.1.2 Trauma Hemostasis
    • 6.1.3 Interventional Hemostasis
    • 6.1.4 Wound Hemostasis
    • 6.1.5 Others
  • 6.2 Hemostatic Gel Market, By Product Type
    • 6.2.1 Thrombin-Based Hemostatic Gel
    • 6.2.2 Collagen-Based Hemostatic Gel
    • 6.2.3 Gelatin-Based Hemostatic Gel
    • 6.2.4 Fibrin-Based Hemostatic Gel
    • 6.2.5 Polysaccharide-Based Hemostatic Gel
  • 6.3 Hemostatic Gel Market, By Ingredient Type
    • 6.3.1 Gelatin
    • 6.3.2 Thrombin
    • 6.3.3 Collagen
    • 6.3.4 Fibrin
    • 6.3.5 Polysaccharide
  • 6.4 Hemostatic Gel Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Hemostatic Gel Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hemostatic Gel market is categorized based on

By Product Type

• Thrombin-Based Hemostatic Gel
• Collagen-Based Hemostatic Gel
• Gelatin-Based Hemostatic Gel
• Fibrin-Based Hemostatic Gel
• Polysaccharide-Based Hemostatic Gel

By Application

• Surgical Hemostasis
• Trauma Hemostasis
• Interventional Hemostasis
• Wound Hemostasis
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Online Stores
• Others

By Ingredient Type

• Gelatin
• Thrombin
• Collagen
• Fibrin
• Polysaccharide

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Medtronic
• Smith & Nephew
• Ethicon, Inc.
• Hemostasis, LLC
• CSL Behring
• Advanced Medical Solutions Group plc
• BD (Becton, Dickinson and Company)
• Z-Medica, LLC
• Cohera Medical, Inc.
• Integra LifeSciences Corporation
• HemaQuell
• Biolife Plasma Services
• Vascular Solutions, Inc.
• Terumo Corporation